Articles tagged with Cancer
Researchers from Dresden University Medicine developed a new treatment approach for relapsed acute myeloid leukemia (AML), combining standard therapy with the BCL2 inhibitor venetoclax. The innovative combination therapy has shown promising efficacy, increasing remission rates to 75% and improving patients' chances of recovery.
A new clinical study aims to improve communication between patients and families about genetic risks of colorectal cancer. The trial will compare two methods of sharing genetic test results with close relatives, with the goal of learning which approach helps more family members get necessary genetic testing.
A study found that only 9% of older adults with advanced cancer prioritize extending survival over maintaining quality of life. The lack of responsiveness of the current oncology care delivery system to patient preference may be a significant issue. This highlights the need for care system changes to prioritize patient needs.
The novel approach outperforms standard CAR-T cell therapy in preclinical studies using mouse models of glioblastoma and ovarian cancer. Armored CAR-T cells eliminate tumors, reshape the tumor environment, and boost immune-cell activity.
Cancer cell-derived small extracellular vesicles can be excreted into urine, according to researchers who tracked their journey in mouse models. The study reveals that glomerular cells actively transport sEVs across the filtration barrier, supporting their use in emerging urine-based cancer diagnostics.
A team led by Paul Bastard aims to discover antibodies that open new avenues for early detection, prevention and treatment of cancer. Ludwig Institute scientists will employ novel protein profiling technologies to capture telltale patterns linking antibody repertoires and disease states.
Researchers from Johns Hopkins Medicine have created the open-source AstroID database to organize and analyze clinical and genetic data from cancer patients. The database allows for the study of multiple tumor types and longitudinal patient experiences, streamlining data collection and analysis.
A team of researchers led by Rice University bioengineer Omid Veiseh is developing a first-of-its-kind regenerative treatment aimed at restoring damaged lymphatic vessels and potentially curing lymphedema. The therapy, called ELIXIR, uses engineered human retinal pigment epithelial cells to rebuild broken lymphatic vessels.
Researchers found that interactions with healthy cells determine a tumor's ability to survive, grow, and progress. The team discovered a 'distress signal' sent by the tumor to nearby fibroblasts creates a supportive micro-environment that shelters the tumor from being cleared.
Recent research from the University of Eastern Finland reveals that pro-inflammatory M1 macrophages accelerate melanoma progression through extracellular vesicle secretion. These vesicles contain inflammatory mediators that activate cancer cells, creating a favourable environment for tumour growth and invasiveness.
Researchers found a high-fat diet accelerates tumor growth and invasion in triple-negative breast cancer, causing an increase in the enzyme MMP1. This dietary condition may lead to a poor prognosis and provide insight into tumor therapies.
A team of scientists discovered that the mannose pathway plays a crucial role in regulating cell fate decisions in low glucose environments, particularly in cancer cells. They found that reducing mannose pathway activity led to impaired N-glycan biosynthesis and activated pro-survival signals, which can contribute to cancer progression.
A study published in Science Advances reveals a mechanism to bind to intrinsically disordered proteins, providing a new approach for therapeutic design. The research, led by Dr. Xavier Salvatella, shows that these proteins adopt more organized conformations when clustering, allowing for selective binding by a drug.
A nationwide Danish study comparing outcomes between patients treated with minimally invasive ablation and surgery found no difference in cancer progression but more frequent local recurrence of the disease following ablation. Ablation patients had shorter hospital stays and fewer complications.
The King Center for Lynch Syndrome will advance research, outreach, education, and patient care for Lynch syndrome, a hereditary condition affecting 1 in 279 individuals. The center will provide cutting-edge research, life-long comprehensive care, and increased awareness for patients and families affected by Lynch syndrome.
A new study introduces an innovative imaging tracer that identifies shifts in fat usage for energy, shedding light on aggressive cancers' lipid-based metabolism. This discovery could lead to targeted therapeutic interventions and improved patient outcomes.
The James P. Allison Institute at UT MD Anderson Cancer Center appoints Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon to advance immunotherapy research. These experts bring expertise in immune therapy resistance, cancer vaccines, bioengineering, tumor evolution, and drug development.
Researchers identified a key gene GATA6 that helps control the 'switch' between aggressive and manageable states in pancreatic cancer cells. By targeting this pathway, combination therapies with standard chemotherapy may improve treatment outcomes.
Researchers found that quantifiable HBV RNA levels are associated with a significantly higher risk of HCC, independent of traditional risk factors. Chronic hepatitis B patients with concurrent liver dysfunction should be intensified under surveillance for HCC.
Researchers developed a bioorthogonal fluorescence probe and matching reporter enzyme that selectively activates at targeted tumor sites, enabling high-contrast tumor visualization with minimal background. This technology has potential for improving cancer surgery outcomes and may also be adapted for targeted drug delivery.
Researchers found that early precancerous cells in pancreas gather into specific clusters and interact with immune cells, weakening the body's ability to fight them. The study provides fresh insight into how pancreatic cancer may begin taking shape years before it is clinically detected.
Renowned cancer clinician Dr. Daniela Matei will lead the Houston Methodist Dr. Mary and Ron Neal Cancer Center, bringing expertise in ovarian cancer treatment and therapeutics. She aims to bridge laboratory science to the clinic, advancing new concepts from bench to bedside.
Researchers found that circulating tumor DNA can predict metastatic risk in patients treated with bladder-sparing treatment for muscle-invasive bladder cancer. The absence of ctDNA predicted favorable outcomes regardless of bladder removal status.
Ancient genetic fragments called L1 elements destabilise the cancer genome years before diagnosis, giving malignant cells more opportunities to grow and adapt. Long-read sequencing technology reveals large-scale structural rearrangements that seed genomic chaos, potentially driving cancer development.
The article summarizes updated recommendations on fertility preservation in people with cancer, considering potential health risks to offspring and treatment side effects. Clinicians should inform patients about available options before treatment initiation.
Polytherapy significantly improves survival outcomes in women with metastatic breast cancer, reducing all-cause mortality by 38% compared to monotherapy. Regular blood pressure medicine adherence also increases survival, especially among Black and Hispanic patients.
A new UCLA study suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with low PSA levels. However, men with higher PSA levels before radiation may see modest improvements in survival and metastasis-free survival.
Researchers found that tumors with androgen receptor alterations experienced poorer outcomes, shorter overall survival, and earlier need for subsequent therapy. Serial liquid biopsies revealed real-time molecular changes linked to treatment pressure.
New CAR T cells engineered to detect low levels of CD70 show promise in eradicating kidney, ovarian, and pancreatic tumors in preclinical models. This breakthrough provides a potential strategy for treating multiple solid tumor types with targeted immunotherapy.
A new study analyzing 519 patients with cancer reveals that financial toxicity significantly impacts not only finances but also psychological resources like hope and social support. As these resources weaken, overall life satisfaction declines.
Researchers at Osaka Metropolitan University found that targeting the glutamine transporter ASCT2 can suppress cell growth and induce apoptosis in synovial sarcoma cells. This study suggests a new approach for treating this aggressive malignant tumor by cutting off its nutrient supply.
Daily aspirin use offers no quick or reliable way to prevent bowel cancer in the general population, increasing risk of serious bleeding. However, it may have potential long-term benefits for people at high genetic risk of colorectal cancer.
A University of Lausanne research team discovered vitamin B7's role in bypassing glutamine addiction in cancer cells. The study found that pyruvate, enabled by pyruvate carboxylase and vitamin B7, fuels cells' energy cycle even without glutamine.
An online experiment with 1,051 US adults suggests flagging potentially false cancer treatment claims on social media can help reduce the spread of misinformation. The study found that intervening and reducing sharing of false information on social media may have a positive impact on public health.
The article discusses recent advances in chimeric antigen receptor T-cell (CAR-T) therapy, highlighting its promise and remaining challenges. Next-generation CAR designs aim to improve specificity and reduce on-target/off-tumor toxicity, while addressing access disparities and equity issues.
A study in Science reveals that a healthy gut microbiota enhances immunotherapy's efficacy against cancer, while antibiotics reduce diversity and may impair treatment. Analysis found specific bacterial species associated with better clinical outcomes.
Scientists developed a new platform using protein-like polymers to target and degrade cancer-driving proteins like MYC and KRAS. The approach triggers cancer cell death, offering hope for treating aggressive and drug-resistant cancers.
A research team has engineered bacteria capable of consuming tumours from the inside out, using a novel tool for cancer treatment. The bacteria, Clostridium sporogenes, are designed to multiply in oxygen-free environments found in solid tumours, where they can effectively target and destroy cancerous cells.
Researchers at UCLA have found a way to supercharge immune cells with a fuel source that tumors can't steal, dramatically improving their ability to survive and attack solid tumors. The approach enables T cells to import cellobiose and convert it into usable glucose inside the cell.
A new study by Harvard T.H. Chan School of Public Health found that US counties near operational nuclear power plants have higher rates of cancer mortality than those farther away. The researchers estimated around 115,000 cancer deaths in the US over the study period attributed to NPP proximity.
A recent study published in CANCER found that adults with cancer who developed mental health conditions within the first year after diagnosis had a significantly higher likelihood of dying over the next few years. The analysis of data from University of California-affiliated hospitals revealed a 51% increased risk of death among those ...
Researchers found that radiation-resistant cancer cells are vulnerable to NK cell-mediated killing due to increased expression of specific cellular membrane proteins, creating an 'evolutionary double-bind'. The combination of radiation therapy and NK cell-based immunotherapy was more effective in suppressing both sensitive and resistan...
The European Association of Nuclear Medicine (EANM) has launched a new award to accelerate alpha radioligand therapy (α-RLT) research in prostate cancer. The EANM Young Scientist Network Award offers €40,000 in funding for promising researchers.
Scientists at Cincinnati Children's Hospital Medical Center have discovered a way to reduce the risk of a lethal side effect in cancer patients treated with immune checkpoint inhibitors. By targeting CD8 T cell-derived tumor necrosis factor, they found that blocking TNF signaling can prevent inflammatory cycle in the heart.
The ESE and ESPE have launched a landmark Joint Clinical Practice Guidance to support structured and effective transition of young people with endocrine conditions. The Guidance provides practical, evidence-based recommendations to ensure continuity, safety and quality of care during this critical phase in a patient's life.
Researchers have engineered a novel CAR-T cell that can be switched off on demand using a cancer drug, offering improved safety and efficacy. The new system, known as DROP-CAR-T, uses a clinically approved drug to disrupt tumor cell binding, preserving the cells for continued treatment.
A recent study sequenced cancer genes in domestic cats, comparing them to human cancer-causing mutations. The researchers identified similar oncogenes and tumor-predisposing genes in both species, which could inform veterinary cancer treatments and human medicine.
Dr. James R. Downing will transition to a faculty role at St. Jude in 2026, leading the institution's global mission after an unprecedented growth period. He played a pivotal role in advancing childhood cancer research and treatment worldwide.
Researchers analyzed tumour samples from almost 500 domestic cats across five countries, identifying specific driver genes that lead to cancer development. The study found similarities between cat and human cancers, including a common driver gene associated with worse prognosis in humans.
Researchers found patients who retreated with docetaxel had longer overall survival and fewer supportive-care needs compared to those switching to cabazitaxel. The study provides evidence-based options for selected patients previously tolerated docetaxel.
Researchers highlight polyploidy-induced senescence as a coordinated biological program that may drive aging, tissue repair, and cancer risk. Polyploidization in healthy tissues could help maintain organ structure and barrier integrity, but its instability can promote chromosomal instability and malignant transformation.
Researchers are developing a new compound that can break down MDM2, a cancer-driving protein often found in triple-negative breast cancer, showing promise in shrinking tumors. The goal is to create an entirely new class of therapies for this aggressive and difficult-to-treat form of the disease.
Researchers at the University of Turku discovered that surface cells of lymphatic vessels in oral cancer contain proteins indicating cell division, strongly predicting disease progression and mortality. Early-stage oral cancers can be identified by changes in these vessels, which may lead to death even with small tumors.
Researchers developed a free-to-use software tool, PSBench, to verify the accuracy of artificial intelligence-based protein structure predictions. The database includes 1.4 million annotated protein models, verified by experts, and provides reliable information for building more accurate AI systems.
A study published in Nature reveals that a protein called lipocalin 2 (LCN2) is produced by stressed cancer cells to shield them from the immune system. Blocking LCN2 with new drugs enables the immune system to target tumor cells, slowing cancer growth in mice.
Researchers at Case Western Reserve University developed a strategy using ultrasound-activated nanobubbles to break down tumor barriers, making tumors softer and more penetrable to treatment-bearing molecules and immune cells. This breakthrough could fast-track therapy to clinical trials for solid tumors like prostate cancer.
A study by RIKEN researchers identifies a MYCN-driven biomarker that predicts the risk of liver cancer. The biomarker, known as the MYCN niche score, uses machine learning to analyze gene expression patterns and indicates whether a tumor-free liver is at high risk for developing tumors.
A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.
A new framework proposes a 'three-strata' model to classify gastrointestinal tract cancers, guiding more precise and effective strategies. The review advocates for chemotherapy-free approaches in highly immunogenic tumors and explores optimized combinations with chemotherapy for intermediate-sensitive tumors.
A multi-institutional effort aims to refine relapse prediction by identifying genetic markers in blood samples from patients with rare blood cancer. Analyzing blood samples from 190 patients, researchers found that tiny traces of persistent NPM1 mutation were linked to worse outcomes and lower survival rates.